Ionis Pharmaceuticals Inc

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis to hold first quarter 2026 financial results webcast

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review